PHG - Philips' Zenition 30 to Boost Image-Guided Surgeries | Benzinga
Koninklijke Philips (NYSE: PHG) recently announced the receipt of FDA 510(k) approval for its Zenition 30 mobile C-arm. The approval is likely to make image-guided surgical procedures available to more patients at a lower cost in the United States.
The new Zenition 30 delivers a special mix of personalized control and image clarity to improve the speed and accuracy of decision-making for a variety of clinical procedures at an affordable cost. It is based on the company's Zenition platform's demonstrated simplicity of use and workflow efficiency.
Price Performance
Over the past six months, PHG's shares have gained 9.6% compared with the industry's rise of 14.7%. The S&P 500 increased 17.8% in the same time frame.
Image Source: Zacks Investment Research
More on Zenition 30
Zenition 30 reduces surgeons' reliance on support staff by providing them with more customization, control, and flexibility over C-arm movement and user settings. This helps address staff shortages that restrict patient access and increase waiting periods. The Zenition 30 also solves the financial issues that affect present hospital systems by lowering the number of support personnel needed during procedures.
Surgeons can treat more patients while also spending more time focusing on each patient because of the intuitive C-arm control provided by the patient table. This results in an improved experience for both people and patients.
With its cutting-edge imaging algorithms, customized user profiles, and flat detector technology ...